SER-101 is a formulation of recombinant human HspB5. Previously known as DC-TAB (Clinical trial ID: NCT02442557).
How does it work?
Large HspB5 multimeric structures preferentially bind to myeloid cells, and up-regulate genes involved in immune tolerance through TLR1/2 engagement.
These myeloid cells are long-lasting and exude potent anti-inflammatory effects.
Lupus nephritis & SER-101
Lupus nephritis is a kidney disorder that afflicts most lupus patients. It is a serious condition that can result in end-stage renal disease if not properly treated.
Current therapies target patient lymphocyte activity as an attempt to avoid further destruction of the kidney. We believe the innate system, particularly myeloid cells, play a major role in lupus nephritis.
Instead of adding another immune suppressant, SerenityBio hypothesizes that targeting myeloid cells using HspB5 will increase response rates and improve effectiveness of the standard of care.
Demonstrated in multiple pre-clinical models
Modulating myeloid cells with SER-101 has been demonstrated in pre-clinical models for MS, Lupus, IBS, COPD, and many others.
Inflammatory Bowel Syndrome
DSS & TNBS-induced colitis